These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1824 related articles for article (PubMed ID: 33945284)

  • 1. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.
    Sajid MI; Moazzam M; Cho Y; Kato S; Xu A; Way JJ; Lohan S; Tiwari RK
    Mol Pharm; 2021 Jun; 18(6):2105-2121. PubMed ID: 33945284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
    Khan M; Adil SF; Alkhathlan HZ; Tahir MN; Saif S; Khan M; Khan ST
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of application of the RNA interference phenomenon in the treatment of new coronavirus infection COVID-19.
    Pashkov EA; Korchevaya ER; Faizuloev EB; Svitich OA; Pashkov EP; Nechaev DN; Zverev VV
    Vopr Virusol; 2021 Sep; 66(4):241-251. PubMed ID: 34545716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.
    Younis NK; Zareef RO; Maktabi MAN; Mahfouz R
    Genet Test Mol Biomarkers; 2021 Feb; 25(2):85-101. PubMed ID: 33596144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?
    Mehta A; Michler T; Merkel OM
    Adv Healthc Mater; 2021 Apr; 10(7):e2001650. PubMed ID: 33506607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.
    Bhandari R; Khanna G; Kuhad A
    Eur J Pharmacol; 2021 Jan; 890():173643. PubMed ID: 33065092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research and Patents on Coronavirus and COVID-19: A Review.
    Aranda P; Wicklein B; Ruiz-Garcia C; Martín-Sampedro R; Darder M; Del Real G; Ruiz-Hitzky E
    Recent Pat Nanotechnol; 2020; 14(4):328-350. PubMed ID: 33087037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Nanotechnology in the COVID-19 Pandemic.
    Yang D
    Int J Nanomedicine; 2021; 16():623-649. PubMed ID: 33531805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
    Forchette L; Sebastian W; Liu T
    Curr Med Sci; 2021 Dec; 41(6):1037-1051. PubMed ID: 34241776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
    Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.
    Chowdhury UF; Sharif Shohan MU; Hoque KI; Beg MA; Sharif Siam MK; Moni MA
    Genomics; 2021 Jan; 113(1 Pt 1):331-343. PubMed ID: 33321203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
    Cao M; Su X; Jiang S
    Stem Cell Reports; 2021 Mar; 16(3):398-411. PubMed ID: 33691145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primed for global coronavirus pandemic: Emerging research and clinical outcome.
    Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S
    Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses.
    Fiorino S; Tateo F; Biase D; Gallo CG; Orlandi PE; Corazza I; Budriesi R; Micucci M; Visani M; Loggi E; Hong W; Pica R; Lari F; Zippi M
    Future Microbiol; 2021 Sep; 16(14):1105-1133. PubMed ID: 34468163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.